The DOI matches its Crossref record; 42 of the 44 references it cites were found in a registry or an index.
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype
Open accessAbstract
Both genome-wide genetic and epigenetic alterations are fundamentally important for the development of cancers, but the interdependence of these aberrations is poorly understood. Glioblastomas and other cancers with the CpG island methylator phenotype (CIMP) constitute a subset of tumours with extensive epigenomic aberrations and a distinct biology. Glioma CIMP (G-CIMP) is a powerful determinant of tumour pathogenicity, but the molecular basis of G-CIMP remains unresolved. Here we show that mutation of a single gene, isocitrate dehydrogenase 1 (IDH1), establishes G-CIMP by remodelling the methylome. This remodelling results in reorganization of the methylome and transcriptome. Examination of the epigenome of a large set of intermediate-grade gliomas demonstrates a distinct G-CIMP phenotype that is highly dependent on the presence of IDH mutation. Introduction of mutant IDH1 into primary human astrocytes alters specific histone marks, induces extensive DNA hypermethylation, and reshapes the methylome in a fashion that mirrors the changes observed in G-CIMP-positive lower-grade gliomas. Furthermore, the epigenomic alterations resulting from mutant IDH1 activate key gene expression programs, characterize G-CIMP-positive proneural glioblastomas but not other glioblastomas, and are predictive of improved survival. Our findings demonstrate that IDH mutation is the molecular basis of CIMP in gliomas, provide a framework for understanding oncogenesis in these gliomas, and highlight the interplay between genomic and epigenomic changes in human cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“IDH mutant gliomas thus manifest a CpG island methylator phenotype (G-CIMP)10,11, though the functional significance of this altered epigenetic state remains unclear.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [11]
In the citing paper
“As a result, D-2HG accumulation in cancer cells expressing mutant IDH results in hypermethylation of histones and CpG islands in DNA (Figueroa et al., 2010; Lu et al., 2012; Turcan et al., 2012).”
From Targeting Metabolism for Cancer Therapy (2017) · cites this paper as Turcan et al., 2012
In the citing paper
“Specifically, owing to the interference with TET family proteins, the mutation causes the CpG island methylator phenotype116,123.”
From Transcription factors as readers and effectors of DNA methylation (2016) · cites this paper as [123]
In the citing paper
“Indeed, IDH-driven gliomas, leukemias and chondrosarcomas display a prominent CpG island hypermethylation, reminiscent of the hypermethylator phenotype seen in SDH- and FH-deficient cancers (Figueroa et al., 2010; Lu et al., 2013; Turcan et al., 2012).”
From The emerging hallmarks of cancer metabolism (2016) · cites this paper as Turcan et al., 2012
In the citing paper
“In the cancer setting, 2-HG has been shown to influence a number of biological processes, including cell differentiation, DNA methylation, and histone methylation (79–82), leading to its classification as an oncometabolite.”
From Fueling Immunity: Insights into Metabolism and Lymphocyte Function (2013) · cites this paper as [82]
In the citing paper
“Like TH17 cells, CD8+ T cells are highly dependent on the activation of HIF-1α and glycolysis, which is responsible for mediating trafficking into hypoxic tumour environments and inflamed tissue147,148.”
From Coupling Krebs cycle metabolites to signalling in immunity and cancer (2018) · cites this paper as [147]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Jones, P. A., & Baylin, S. B. (2007) · Cell · doi:10.1016/j.cell.2007.01.029 · Cited by 4,515
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
Self-citationConsed: a graphical tool for sequence finishing.Preprint
Gordon, D., Abajian, C., & Green, P. (1998) · Genome Research · doi:10.1101/gr.8.3.195 · Cited by 3,706
CNS stem cells express a new class of intermediate filament protein
Lendahl, U., Zimmerman, L. B., & McKay, R. D. G. (1990) · Cell · doi:10.1016/0092-8674(90)90662-x · Cited by 3,164
Cited by
Sorted by citations
Items 901–1,000 of 1,002
Yedier-Bayram, O., Gokbayrak, B., Kayabölen, A., Aksu, A. C., Cavga, A. D., Cingöz, A., Kala, E. Y., Karabiyik, G., Günsay, R., Esin, B., et al. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05146-4 · Cited by 26
The expression of Hexokinase 2 and its hub genes are correlated with the prognosis in glioma
Huang, Y., Ouyang, F., Yang, F., Zhang, N., Zhao, W., Xu, H., & Yang, X. (2022) · BMC Cancer · doi:10.1186/s12885-022-10001-y · Cited by 30
Methylation Profiling in Diffuse Gliomas: Diagnostic Value and Considerations
Wenger, A., & Carén, H. (2022) · Cancers · doi:10.3390/cancers14225679 · Cited by 27
Characterizing crosstalk in epigenetic signaling to understand disease physiology
Lempiäinen, J. K., & Garcia, B. A. (2023) · Biochemical Journal · doi:10.1042/bcj20220550 · Cited by 29
Cancer stem cells in brain tumors: From origin to clinical implications
Lin, S., Li, K., & Qi, L. (2023) · MedComm · doi:10.1002/mco2.341 · Cited by 27
Whitehall, V., Dumenil, T. D., McKeone, D., Bond, C., Bettington, M. L., Buttenshaw, R. L., Bowdler, L. M., Montgomery, G. W., Wockner, L. F., & Leggett, B. (2014) · Epigenetics · doi:10.4161/15592294.2014.971624 · Cited by 26
Distinct IDH1/IDH2 mutation profiles in purely insular versus paralimbic WHO Grade II gliomas
Gozé, C., Mansour, L., Rigau, V., & Duffau, H. (2013) · Journal of neurosurgery · doi:10.3171/2012.11.jns121100 · Cited by 26
TP53, MSH4, and LATS1 Germline Mutations in a Family with Clustering of Nervous System Tumors
Kim, Y.-H., Ohta, T., Oh, J. E., Calvez‐Kelm, F. L., McKay, J., Voegele, C., Durand, G., Mittelbronn, M. G. A., Kleihues, P., Paulus, W., et al. (2014) · American Journal Of Pathology · doi:10.1016/j.ajpath.2014.05.017 · Cited by 26
Kang, X., Chen, R., Zhang, J., Li, G., Dai, P., Chen, C., & Wang, H. (2015) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2015.16.8.3355 · Cited by 26
Polívka, J., Pešta, M., Pitule, P., Hes, O., Holubec, L., Polívka, J., Kubíková, T., & Tonar, Z. (2018) · Oncotarget · doi:10.18632/oncotarget.24536 · Cited by 28
Mathios, D., Hwang, T., Xia, Y., Phallen, J. A., Rui, Y., See, A. P., Maxwell, R., Belcaid, Z., Casaos, J., Burger, P. C., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32587 · Cited by 26
Ferreira, M. S. V., Sørensen, M. D., Pusch, S., Beier, D., Bouillon, A., Kristensen, B. W., Brümmendorf, T. H., Beier, C. P., & Beier, F. (2020) · Journal of Neuro-Oncology · doi:10.1007/s11060-020-03394-y · Cited by 25
Chushig-Muzo, D., Soguero-Ruíz, C., Engelbrecht, A. P., de Miguel-Bohoyo, P., & Mora-Jiménez, I. (2020) · IEEE Access · doi:10.1109/access.2020.3012082 · Cited by 26
Garrett-Bakelman, F. E., & Melnick, A. M. (2016) · Epigenomics · doi:10.2217/epi-2016-0008 · Cited by 25
Oncometabolite 2-hydroxyglutarate regulates anti-tumor immunity
Cai, M., Zhao, J., Ding, Q., & Wei, J. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e24454 · Cited by 30
Gretarsson, K. H., Abini-Agbomson, S., Gloor, S. L., Weinberg, D. N., McCuiston, J. L., Kumary, V. U. S., Hickman, A. R., Sahu, V., Lee, R., Xu, X., et al. (2024) · Science Advances · doi:10.1126/sciadv.adp0975 · Cited by 27
Hypoxia-induced epigenetic regulation of breast cancer progression and the tumour microenvironment
Capatina, A. L., Malcolm, J. R., Stenning, J., Moore, R. L., Bridge, K. S., Brackenbury, W. J., & Holding, A. N. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1421629 · Cited by 31
CD8+ T-cell exhaustion: Impediment to triple-negative breast cancer (TNBC) immunotherapy
Feng, D., Pu, D., Ren, J., Liu, M., Zhang, Z., Liu, Z., & Li, J. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189193 · Cited by 26
Mapping the developmental trajectory of human astrocytes reveals divergence in glioblastoma
Sojka, C., Wang, H. V., Bhatia, T. N., Li, Y., Chopra, P., Sing, A., Voss, A. J., King, A. T., Wang, F., Joseph, K., et al. (2025) · Nature Cell Biology · doi:10.1038/s41556-024-01583-9 · Cited by 24
In Vivo Modeling of Malignant Glioma
Kegelman, T. P., Hu, B., Emdad, L., Das, S. K., Sarkar, D., & Fisher, P. B. (2014) · Advances in cancer research · doi:10.1016/b978-0-12-800249-0.00007-x · Cited by 23
5-Hydroxymethylcytosine: a Potential Therapeutic Target in Cancer
Rodger, E. J., Chatterjee, A., & Morison, I. M. (2014) · Epigenomics · doi:10.2217/epi.14.39 · Cited by 25
Penterling, C., Drexler, G. A., Böhland, C., Stamp, R., Wilke, C., Braselmann, H., Caldwell, R. B., Reindl, J., Girst, S., Greubel, C., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0156599 · Cited by 25
Epigenetic Drugs for Cancer and Precision Medicine
Verma, M., & Kumar, V. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-811060-7.00021-8 · Cited by 26
A narrative review of research progress on drug therapies for glioblastoma multiforme
Zheng, X., Tang, Q., Ren, L., Liu, J., Wan, L., Fu, W., Wang, J., & Du, G. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-8017 · Cited by 26
Kusi, M., Zand, M., Lin, L., Chen, M., Lopez, A., Lin, C.-L., Wang, C., Lucio, N. L. L., Kirma, N. B., Ruan, J., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2021.110220 · Cited by 28
The Role of DNA Methylation and DNA Methyltransferases in Cancer
Weisenberger, D. J., Lakshminarasimhan, R., & Liang, G. (2022) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-11454-0_13 · Cited by 27
Lee, K.-H., Kim, S., Kim, E. E., Shim, Y., Won, J., Park, C., Choi, S. H., Yun, H., Lee, H., & Park, S. (2023) · Scientific Reports · doi:10.1038/s41598-023-32153-y · Cited by 25
Oncohistones and disrupted development in pediatric-type diffuse high-grade glioma
Ocasio, J. K., Budd, K. M., Roach, J. T., Andrews, J. M., & Baker, S. J. (2023) · Cancer and Metastasis Reviews · doi:10.1007/s10555-023-10105-2 · Cited by 27
Medina-Cleghorn, D., & Nomura, D. K. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.07.007 · Cited by 25
Anaplastic glioma: current treatment and management
Rhun, É. L., Taillibert, S., & Chamberlain, M. C. (2015) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2015.1042455 · Cited by 25
IDH1 mutation detection by droplet digital PCR in glioma
Wang, J., Zhao, Y.-Y., Li, J.-F., Guo, C., Chen, F.-R., Su, H.-K., Zhao, H., Long, Y., Shao, J., To, S. S. T., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5630 · Cited by 25
Prognostic relevance of miRNA-155 methylation in anaplastic glioma
Schliesser, M. G., Claus, R., Hielscher, T., Grimm, C., Weichenhan, D., Blaes, J., Wiestler, B., Hau, P., Schramm, J., Sahm, F., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.13452 · Cited by 25
Epigenetics of pheochromocytoma and paraganglioma
Björklund, P., & Backman, S. (2017) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.06.016 · Cited by 25
Jin, Z., Feng, H., Liang, J., Jing, X., Zhao, Q., Zhan, L., Shen, B., Cheng, X., Su, L., & Qiu, W. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-03089-2 · Cited by 25
The role of vorasidenib in the treatment of isocitrate dehydrogenase-mutant glioma
de la Fuente, M. I., Touat, M., van den Bent, M. J., Preusser, M., Peters, K. B., Young, R. J., Huang, R. Y., Ellingson, B. M., Capper, D., Phillips, J. J., et al. (2024) · Neuro-Oncology · doi:10.1093/neuonc/noae259 · Cited by 28
DiME: A Scalable Disease Module Identification Algorithm with Application to Glioma Progression
Liu, Y., Tennant, D. A., Zhu, Z., Heath, J. K., Yao, X., & He, S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0086693 · Cited by 24
Kouskoumvekaki, I. A., Shublaq, N. W., & Brunak, S. (2013) · Briefings in Bioinformatics · doi:10.1093/bib/bbt055 · Cited by 24
Metabolic, autophagic, and mitophagic activities in cancer initiation and progression
Hjelmeland, A. B., & Zhang, J. (2016) · Biomedical Journal · doi:10.1016/j.bj.2015.10.002 · Cited by 24
Waker, C. A., & Lober, R. M. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-32-9636-7_18 · Cited by 24
Extracellular glutamate and IDH1R132H inhibitor promote glioma growth by boosting redox potential
Tiburcio, P. D. B., Gillespie, D. L., Jensen, R. L., & Huang, E. L. (2020) · Journal of Neuro-Oncology · doi:10.1007/s11060-019-03359-w · Cited by 25
Mehrjardi, N. Z., Hänggi, D., & Kahlert, U. D. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-03196-0 · Cited by 23
Crake, R., Burgess, E. R., Royds, J. A., Phillips, E., Vissers, M. C. M., & Dachs, G. U. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.619300 · Cited by 25
Wang, H., Wang, X., Xu, L., Zhang, J., & Cao, H. (2021) · Scientific Reports · doi:10.1038/s41598-021-91382-1 · Cited by 24
Levy, J., Chen, Y., Azizgolshani, N., Petersen, C. L., Titus, A., Moen, E. L., Vaickus, L. J., Salas, L. A., & Christensen, B. C. (2021) · npj Systems Biology and Applications · doi:10.1038/s41540-021-00193-7 · Cited by 26
Maleszewska, M., & Kaminska, B. (2015) · Future Oncology · doi:10.2217/fon.15.171 · Cited by 25
Imaging biomarkers in primary brain tumours
Lopci, E., Franzese, C., Grimaldi, M., Zucali, P. A., Navarria, P., Simonelli, M., Bello, L., Scorsetti, M., & Chiti, A. (2014) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2971-8 · Cited by 24
Cheng, W., Li, M., Jiang, Y., Zhang, C., Cai, J., Wang, K., & Wu, A. (2015) · Journal of neurosurgery · doi:10.3171/2015.5.jns142437 · Cited by 24
Chitneni, S. K., Yan, H., & Zalutsky, M. R. (2018) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.7b00478 · Cited by 24
Casey, R. T., ten Hoopen, R., Ochoa, E., Challis, B., Whitworth, J., Smith, P., Martín, J., Clark, G. R., Rodger, F., Maranian, M. J., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-46124-9 · Cited by 24
Kotredes, K. P., Razmpour, R., Lutton, E. M., Alfonso‐Prieto, M., Ramirez, S. H., & Gamero, A. M. (2019) · Oncotarget · doi:10.18632/oncotarget.26848 · Cited by 24
Tumor mutational burden predicts survival in patients with low-grade gliomas expressing mutated IDH1
Alghamri, M. S., Thalla, R., Avvari, R., Dabaja, A. A., Taher, A. W., Zhao, L., Ulintz, P., Castro, M. G., & Lowenstein, P. R. (2020) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdaa042 · Cited by 25
The immunology of brain tumors
Bunse, L., Bunse, T., Kilian, M., Quintana, F. J., & Platten, M. (2025) · Science Immunology · doi:10.1126/sciimmunol.ads0449 · Cited by 28
Isocitrate dehydrogenase mutations in chondrosarcoma
Azzi, G., Velez, M., & Mathias-Machado, M. C. (2014) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000092 · Cited by 23
Gene Expression Profiling Stratifies IDH1-Mutant Glioma with Distinct Prognoses
Cheng, W., Ren, X., Zhang, C., Cai, J., Han, S., & Wu, A. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-0150-6 · Cited by 24
Huang, G.-H., Du, L., Li, N., Zhang, Y., Xiang, Y., Tang, J., Xia, S., Zhang, E. E., & Lv, S.-Q. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.06.007 · Cited by 23
Identification of a long noncoding RNA signature to predict outcomes of glioblastoma
Li, D., Lu, J., Li, H., Qi, S., & Yu, L. (2019) · Molecular Medicine Reports · doi:10.3892/mmr.2019.10184 · Cited by 23
Mutant IDH1 promotes phagocytic function of microglia/macrophages in gliomas by downregulating ICAM1
Ma, D., Zhan, D., Fu, Y., Wei, S., Lal, B., Wang, J., Li, Y.-Q., López-Bertoni, H., Yalçın, F., Dzaye, O. D. A., et al. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.05.038 · Cited by 23
Connections between metabolism and epigenetic modifications in cancer
Wang, G., & Han, J. J. (2021) · Medical Review · doi:10.1515/mr-2021-0015 · Cited by 27
DNA damage in IDH-mutant gliomas: mechanisms and clinical implications
Shi, D. D., Anand, S., Abdullah, K. G., & McBrayer, S. K. (2022) · Journal of Neuro-Oncology · doi:10.1007/s11060-022-04172-8 · Cited by 22
The role of mutation of metabolism-related genes in genomic hypermethylation
Waterfall, J. J., Killian, J. K., & Meltzer, P. S. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.08.003 · Cited by 23
IDHmutations: new genetic signatures in cholangiocarcinoma and therapeutic implications
Borger, D. R., & Zhu, A. X. (2012) · Expert Review of Anticancer Therapy · doi:10.1586/era.12.32 · Cited by 23
Ohno, M., Narita, Y., Miyakita, Y., Matsushita, Y., Yoshida, A., Fukushima, S., Ichimura, K., & Shibui, S. (2013) · Brain Tumor Pathology · doi:10.1007/s10014-013-0140-6 · Cited by 23
Wang, Q., Xiang, B., Deng, W., Wu, J.-Y., Li, M., Ma, X., Wang, Y., Jiang, L., McAlonan, G. M., Chua, S. E., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0075083 · Cited by 26
TLX—Its Emerging Role for Neurogenesis in Health and Disease
Sobhan, P. K., & Funa, K. (2016) · Molecular Neurobiology · doi:10.1007/s12035-015-9608-1 · Cited by 24
Molecular Genetics of Secondary Glioblastoma
Mansouri, A., Karamchandani, J., & Das, S. (2017) · Codon Publications eBooks · doi:10.15586/codon.glioblastoma.2017.ch2 · Cited by 23
Deregulacja mechanizmów epigenetycznych w nowotworach Marta Maleszewska*,
Maleszewska, M., Wojtaś, B., & Kamińska, B. (2018) · Postępy Biochemii · doi:10.18388/pb.2018_125 · Cited by 23
In vivo efficacy of mutant IDH1 inhibitor HMS-101 and structural resolution of distinct binding site
Chaturvedi, A., Goparaju, R., Gupta, C., Weder, J., Klünemann, T., Cruz, M. M. A., Kloos, A., Görlich, K., Schottmann, R., Othman, B., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0582-x · Cited by 25
Qi, C., Lei, L., Hu, J., Wang, G., Liu, J., & Ou, S. (2020) · Journal of Molecular Neuroscience · doi:10.1007/s12031-020-01620-w · Cited by 23
Zhao, M., Shao, Y., Xu, J., Zhang, B., Li, C., & Gong, J. (2021) · OncoTargets and Therapy · doi:10.2147/ott.s273264 · Cited by 23
Wang, K., Wang, Y., Ma, J., Wang, J., Li, S., Jiang, T., & Dai, J. (2015) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2014.15.24.10893 · Cited by 23
Classification of brain tumours from MR spectra: the INTERPRET collaboration and its outcomes
Julià‐Sapé, M., Griffiths, J. R., Tate, A. R., Howe, F. A., Acosta, D., Postma, G., Underwood, J., Majós, C., & Arús, C. (2015) · NMR in Biomedicine · doi:10.1002/nbm.3439 · Cited by 23
IDH-mutant gliomas arise from glial progenitor cells harboring the initial driver mutation
Park, J. W., Kwak, J., Kim, K. W., Jung, S., Nam, C. H., Kim, H. J., Lee, S. M., Choi, C., Ahn, Y., Park, J., et al. (2026) · Science · doi:10.1126/science.adt0559 · Cited by 23
Boyd, N., Walker, K. D., Ayokanmbi, A., Gordon, E. R., Whetsel, J., Smith, C. M., Sánchez, R. G., Lubin, F. D., Chakraborty, A., Tran, A. N., et al. (2019) · Stem Cells · doi:10.1002/stem.2969 · Cited by 21
Xia, X., Cao, F., Yuan, X., Zhang, Q., Chen, W., Yu, Y., Xiao, H., Han, C., & Yao, S. (2019) · PeerJ · doi:10.7717/peerj.7974 · Cited by 22
He, Q., Chen, J., Xie, Z., & Chen, Z. (2022) · Cancers · doi:10.3390/cancers14235779 · Cited by 24
Epigenetic Regulators of DNA Cytosine Modification: Promising Targets for Cancer Therapy
Jung, I., An, J., & Ko, M. (2023) · Biomedicines · doi:10.3390/biomedicines11030654 · Cited by 22
Martin, K. C., Ma, C., & Yip, S. S. F. (2023) · Brain Sciences · doi:10.3390/brainsci13050817 · Cited by 28
HDAC1 and HDAC6 are essential for driving growth in IDH1 mutant glioma
Garrett, M. C., Albano, R., Carnwath, T., Elahi, L. S., Behrmann, C. A., Pemberton, M., Woo, D., O'Brien, E. J., VanCauwenbergh, B., Perentesis, J. P., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-33889-3 · Cited by 27
Epidemiology and survival of adult-type diffuse glioma in Belgium during the molecular era
Pinson, H., Silversmit, G., Vanhauwaert, D. J., Vanschoenbeek, K., Okito, J.-P. K., Vleeschouwer, S. D., Boterberg, T., & Gendt, C. D. (2023) · Neuro-Oncology · doi:10.1093/neuonc/noad158 · Cited by 28
DNA hypermethylation and 1p Loss silence NHE‐1 in oligodendroglioma
Blough, M. D., Al‐Najjar, M., Chesnelong, C., Binding, C., Rogers, A. D., Luchman, H. A., Kelly, J. J., Fliegel, L., Morozova, O., Yip, S. S. F., et al. (2012) · Annals of Neurology · doi:10.1002/ana.23610 · Cited by 22
Hill, V. K., Shinawi, T., Ricketts, C. J., Krex, D., Schackert, G., Bauer, J., Wei, W., Cruickshank, G. S., Maher, E. R., & Latif, F. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-506 · Cited by 22
Etcheverry, A., Aubry, M., Idbaïh, A., Vauléon, É., Marie, Y., Meneï, P., Boniface, R., Figarella-Branger, D. F., Karayan, L., Quillien, V., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0104455 · Cited by 22
Sheyhidin, I., Kelimu, A., Xie, R., Zhang, K., Zhuang, Z., & Mamtimin, B. (2016) · Neurology India · doi:10.4103/0028-3886.177606 · Cited by 22
Fontana, L., Tabano, S. M., Bonaparte, E., Marfia, G., Pesenti, C., Falcone, R., Augello, C., Carlessi, N., Silipigni, R., Guerneri, S., et al. (2016) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlw052 · Cited by 22
Benešová, M., Trejbalová, K., Kučerová, D., Vernerová, Z., Hron, T., Szabó, Á., Amouroux, R., Klézl, P., Hájková, P., & Hejnar, J. (2017) · Molecular Carcinogenesis · doi:10.1002/mc.22638 · Cited by 22
Lauber, C., Klink, B., & Seifert, M. (2018) · BMC Cancer · doi:10.1186/s12885-018-4251-7 · Cited by 22
Aspartate beta-hydroxylase promotes cholangiocarcinoma progression by modulating RB1 phosphorylation
Huang, C., Iwagami, Y., Zou, J., Casulli, S., Lu, S., Nagaoka, K., Ji, C., Ogawa, K., Cao, K. Y., Gao, J., et al. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.04.041 · Cited by 22
Auezova, R., Ivanova, N. E., Akshulakov, S., Жетписбаев, Б. Б., Kozhakhmetova, A., Ryskeldiyev, N., Mustafin, K., Teltayev, D., & Auezova, L. (2019) · Cancer Management and Research · doi:10.2147/cmar.s195754 · Cited by 22
Targeting ADP-ribosylation by PARP inhibitors in acute myeloid leukaemia and related disorders
Faraoni, I., Giansanti, M., Voso, M. T., Lo‐Coco, F., & Graziani, G. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.04.019 · Cited by 23
The clinical significance of isocitrate dehydrogenase 2 in esophageal squamous cell carcinoma.
Chen, X., Xu, W., Wang, C., Liu, F., Guan, S., Sun, Y., Wang, X., An, D., Wen, Z., Chen, P., et al. (2017) · PubMed Central · Cited by 22
Promising Molecular Targets for the Targeted Therapy of Biliary Tract Cancers: An Overview
Yang, W., & Sun, Y. (2021) · OncoTargets and Therapy · doi:10.2147/ott.s297643 · Cited by 22
Advances in genetic and epigenetic analyses of gliomas: a neuropathological perspective
Tsankova, N. M., & Canoll, P. (2014) · Journal of Neuro-Oncology · doi:10.1007/s11060-014-1499-x · Cited by 21
Zhang, L., Qi, M., Feng, T., Hu, J., Wang, L., Li, X., Gao, W. Q., Liu, H., Jiao, M., Wu, Z., et al. (2018) · Neoplasia · doi:10.1016/j.neo.2017.12.001 · Cited by 21
Seifert, M., Schackert, G., Temme, A., Schröck, E., Deutsch, A., & Klink, B. (2020) · Cancers · doi:10.3390/cancers12061696 · Cited by 22
Epigenetic regulation of cancer stem cell and tumorigenesis
Zhu, K., Xie, V. K., & Huang, S. (2020) · Advances in cancer research · doi:10.1016/bs.acr.2020.05.001 · Cited by 21
Identification of an epigenetic prognostic signature for patients with lower‐grade gliomas
Yu, H., Zhang, D., & Lian, M. (2021) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13587 · Cited by 21
Glioma Stem-Like Cells and Metabolism: Potential for Novel Therapeutic Strategies
Harland, A. J., Liu, X., Ghirardello, M., Galán, M. C., Perks, C. M., & Kurian, K. M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.743814 · Cited by 21
IDH1/2 Mutations in Cancer Stem Cells and Their Implications for Differentiation Therapy
Molenaar, R. J., & Wilmink, J. W. (2021) · Journal of Histochemistry & Cytochemistry · doi:10.1369/00221554211062499 · Cited by 22
Complex role of HIF in cancer: the known, the unknown, and the unexpected
Huang, E. L., Tiburcio, P. D. B., & Choi, H. (2014) · Hypoxia · doi:10.2147/hp.s50651 · Cited by 20
McCarthy, N. J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3248 · Cited by 21
Metadata
- Authors
- Turcan, S., Rohle, D., Goenka, A., Walsh, L. A., Fang, F., Yilmaz, E., Campos, C., Fabius, A. W. M., Lu, C., Ward, P. S., Thompson, C. B., Kaufman, A., Guryanova, O., Levine, R., Heguy, A., Viale, A., Morris, L. G. T., Huse, J. T., Mellinghoff, I. K., & Chan, T. A.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Corresponding author
- Mellinghoff, Ingo K.
- Chan, Timothy A.
- ORCID
- Venue
- Nature
- Published
- 2012-02-15
- Volume
- 483
- Issue
- 7390
- Pages
- 479-483
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3351699
- OpenAlex
- W1988756388
- Cited by
- 1,974
- References
- 44
- Citations by year
- 2026: 90 · 2025: 92 · 2024: 104 · 2023: 100 · 2022: 136 · 2021: 148 · 2020: 140 · 2019: 142 · 2018: 169 · 2017: 144 · 2016: 163 · 2015: 154 · 2014: 153 · 2013: 152 · 2012: 83
- FWCI
- 82.33
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Cancer Institute (F31CA260794, R01CA154767, U54CA143798, P30CA008748)
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- IDH1 mutation, glioma, CpG island methylator phenotype, DNA hypermethylation, 2-hydroxyglutarate, oncometabolites, histone demethylation, methylome, astrocytes, gliomagenesis, hypoxia-inducible factor, epigenetic reprogramming
- MeSH terms
- Astrocytes, Cell Survival, Cells, Cultured, Gene Expression Regulation, Glioblastoma, Glioma, Histones, Humans, Isocitrate Dehydrogenase, Mutation, Phenotype, Tumor Cells, Cultured, CpG Islands, DNA Methylation, Epigenesis, Genetic, Metabolome, HEK293 Cells, Epigenomics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
